Cargando…

Selected Serum Biomarkers (Leptin, Chromogranin A, CA19-9, CEA) in Patients with Pancreatic Neuroendocrine Neoplasm and Associations with Metabolic Syndrome

SIMPLE SUMMARY: Pancreatic neuroendocrine neoplasms (PanNENs) represent approximately 30% of all gastro-entero-pancreatic NENs. According to current knowledge, the association between PanNENs and metabolic syndrome (MS) is not known. The study aimed to assess the relationships between selected serum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosiek, Violetta, Bocian-Jastrzębska, Agnes, Kos-Kudła, Beata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137194/ https://www.ncbi.nlm.nih.gov/pubmed/37190276 http://dx.doi.org/10.3390/cancers15082348

Ejemplares similares

Assessment of the Role of Leptin and Adiponectinas Biomarkers in Pancreatic Neuroendocrine Neoplasms
por: Bocian-Jastrzębska, Agnes, et al.
Publicado: (2023)

Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms
por: Rosiek, Violetta, et al.
Publicado: (2023)

Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm
por: Rosiek, Violetta, et al.
Publicado: (2023)

Role of Leptin and Adiponectin in Carcinogenesis
por: Bocian-Jastrzębska, Agnes, et al.
Publicado: (2023)

Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues
por: Rosiek, Violetta, et al.
Publicado: (2023)

NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis
por: Malczewska, Anna, et al.
Publicado: (2020)

Clinical Usefulness of Plasma Chromogranin A in Pancreatic Neuroendocrine Neoplasm
por: Paik, Woo Hyun, et al.
Publicado: (2013)

The Risk of Venous Thromboembolism in Neuroendocrine Neoplasms
por: Wójcik-Giertuga, Monika, et al.
Publicado: (2023)

NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
por: Malczewska, Anna, et al.
Publicado: (2019)

Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
por: Tomita, Tatsuo
Publicado: (2020)

Chromogranin A and Its Fragments as Regulators of Small Intestinal Neuroendocrine Neoplasm Proliferation
por: Giovinazzo, Francesco, et al.
Publicado: (2013)

Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm
por: Wang, Yu-hong, et al.
Publicado: (2014)

Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study
por: Kos-Kudła, Beata
Publicado: (2015)

Assessment of the Concentration of Endogenous Factors Regulating Angiogenesis, VASH-1 and VEGF-A, in the Blood Serum of Patients with Neuroendocrine Neoplasms
por: Strzelczyk, Janusz, et al.
Publicado: (2022)

Chromogranin A Tubulopathy: Differing Histopathologic Patterns of Acute Tubular Injury in the Setting of Neuroendocrine Neoplasms
por: Sekulic, Miroslav, et al.
Publicado: (2019)

Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas
por: Qiao, Xin-Wei, et al.
Publicado: (2014)

Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors
por: Hijioka, Masayuki, et al.
Publicado: (2014)

Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma
por: Lee, Kyong Joo, et al.
Publicado: (2013)

Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma
por: Ermiah, Eramah, et al.
Publicado: (2022)

Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors
por: Tseng, Chao-Ming, et al.
Publicado: (2018)

The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.
por: Lundin, J., et al.
Publicado: (1994)

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
por: Haglund, C.
Publicado: (1986)

EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms
por: Venugopal, Abhirami, et al.
Publicado: (2022)

Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors
por: Kövesdi, Annamária, et al.
Publicado: (2020)

Serum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas—A Preliminary Study
por: Skubisz, Karolina, et al.
Publicado: (2023)

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
por: Haglund, C., et al.
Publicado: (1994)

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
por: Baudin, E., et al.
Publicado: (1998)

Imaging of Pancreatic Neuroendocrine Neoplasms
por: Chiti, Giuditta, et al.
Publicado: (2021)

P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
por: Nielsen, Kirstine, et al.
Publicado: (2020)

Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma
por: Wang, Wei, et al.
Publicado: (2016)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
por: Di Giacinto, Paola, et al.
Publicado: (2018)

Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors
por: Baekdal, Jonas, et al.
Publicado: (2020)

Surgical management of pancreatic neuroendocrine neoplasms
por: Partelli, Stefano, et al.
Publicado: (2014)

Imaging presentation of pancreatic neuroendocrine neoplasms
por: Ciaravino, Valentina, et al.
Publicado: (2018)

Diabetes in Patients With Pancreatic Neuroendocrine Neoplasms
por: Zhuge, Xiaoling, et al.
Publicado: (2020)

An Insight on Functioning Pancreatic Neuroendocrine Neoplasms
por: Bevere, Michele, et al.
Publicado: (2023)

Management of Functional Pancreatic Neuroendocrine Neoplasms
por: Magi, Ludovica, et al.
Publicado: (2023)

Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei
por: Liang, Lei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m9sb4go3vnen8p45ltejgi76e8